Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
60%
Ph phase_4
1
20%
Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 33 (60.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed480%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

NCT04737928
completedphase_4

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

NCT02802137
unknownphase_3

Switching From Preserved to Preserved-free Treatments for Glaucoma.

NCT01433900
completedphase_3

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

NCT01087671
completedphase_3

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

NCT00596791

Clinical Trials (5)

Showing 5 of 5 trials
NCT04737928Not Applicable

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Completed
NCT02802137Phase 4

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

Completed
NCT01433900Phase 3

Switching From Preserved to Preserved-free Treatments for Glaucoma.

Unknown
NCT01087671Phase 3

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

Completed
NCT00596791Phase 3

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5